Skip to content
Screener

Liabilities at other companies

Cal-Maine Foods logo
Cal-Maine FoodsCALM
$467.04M-9.9%
NewAmsterdam Pharma Company logo
NewAmsterdam Pharma CompanyNAMS
$73.03M+99.5%
SharkNinja logo
SharkNinjaSN
$2.75B
United Therapeutics logo
United TherapeuticsUTHR
$819.8M+11.6%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$297.67M-22.3%
Owens Corning logo
Owens CorningOC
$8.92B-3.9%

Other financials

Income statement

See full
Revenue$7.7M-60.1%
Gross profit-$3.8M-307%
Operating income-$135.0M+23.4%
Net income-$131.0M+23.8%
EPS (diluted)-$0.25+39.0%

Balance sheet

See full
Cash & equivalents$556.8M+4.3%
Total debt$80.5M-27.2%
Total equity$915.0M-0.5%
Total assets$1.2B-6.9%

Cash flow

See full
Operating cash flow-$105.9M-38.6%
CapEx$44.0K-98.6%
Free cash flow-$106.0M-33.2%

Valuation

See full
Market cap$1.68B-29.3%
Enterprise value$1.21B-38.3%
P/S30.7×-6.2×

Profitability

See full
Gross margin3.5%
Operating margin-991.7%-13.7pp
Net margin-945.9%-52.4pp
FCF margin-642.2%+36.1pp

Returns & leverage

See full
Return on equity-56.6%-14.5pp
Debt / equity0.1×0.0×
Current ratio+1.5×

Where this comes from

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 6:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001601830-26-000098
Line itemJune 30, 2026December 31, 2025
Notes payable and financing lease liabilities, non-current4,7539,564
Deferred tax liabilities18,31323,255
Other liabilities, non-current2,7022,080
Total liabilities297,665343,265
Commitments and contingencies (Note 7)
Stockholders’ equity
Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of June 30, 2026 and December 31, 2025; 534,120,235 shares (Class A 533,191,318, Class B — and Exchangeable 928,917) and 528,182,693 shares (Class A 521,831,046, Class B 5,547,334 and Exchangeable 804,313) issued and outstanding as of June 30, 2026 and December 31, 2025, respectively55
Additional paid-in capital3,211,5153,170,145

Item 1. Financial Statements (unaudited)

FAQ

What is Recursion Pharmaceuticals, Inc.'s liabilities?
Recursion Pharmaceuticals, Inc. (RXRX) reported liabilities of $297.67M in Q2 2026.
How has Recursion Pharmaceuticals, Inc.'s liabilities changed year-over-year?
Recursion Pharmaceuticals, Inc.'s liabilities decreased by 22.3% year-over-year, from $383.21M to $297.67M.
What is the long-term trend for Recursion Pharmaceuticals, Inc.'s liabilities?
Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s liabilities has grown at a 43.4% compound annual growth rate (CAGR), from $56.56M to $343.27M.
What does liabilities mean?
Liabilities as reported by Recursion Pharmaceuticals, Inc. Class A Common Stock.

Ask your AI about Recursion Pharmaceuticals, Inc.'s liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude